IL252596A0 - History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseases - Google Patents
History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseasesInfo
- Publication number
- IL252596A0 IL252596A0 IL252596A IL25259617A IL252596A0 IL 252596 A0 IL252596 A0 IL 252596A0 IL 252596 A IL252596 A IL 252596A IL 25259617 A IL25259617 A IL 25259617A IL 252596 A0 IL252596 A0 IL 252596A0
- Authority
- IL
- Israel
- Prior art keywords
- liver
- treatment
- gastrointestinal diseases
- fxr agonists
- azabicyclooctane
- Prior art date
Links
- QUIJMHDIAFOPRK-UHFFFAOYSA-N 1-cyclooctylazocane Chemical class C1CCCCCCC1N1CCCCCCC1 QUIJMHDIAFOPRK-UHFFFAOYSA-N 0.000 title 1
- 208000018522 Gastrointestinal disease Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 210000004185 liver Anatomy 0.000 title 1
- 208000019423 liver disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462093586P | 2014-12-18 | 2014-12-18 | |
| PCT/IB2015/059450 WO2016097933A1 (en) | 2014-12-18 | 2015-12-08 | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL252596A0 true IL252596A0 (en) | 2017-07-31 |
Family
ID=54979887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL252596A IL252596A0 (en) | 2014-12-18 | 2017-06-01 | History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20170368038A1 (enExample) |
| EP (1) | EP3233083A1 (enExample) |
| JP (1) | JP2017537960A (enExample) |
| KR (1) | KR20170095965A (enExample) |
| CN (1) | CN107106555A (enExample) |
| AU (1) | AU2015365481B2 (enExample) |
| BR (1) | BR112017011972A2 (enExample) |
| CA (1) | CA2970866A1 (enExample) |
| CL (1) | CL2017001566A1 (enExample) |
| IL (1) | IL252596A0 (enExample) |
| MX (1) | MX2017008057A (enExample) |
| PH (1) | PH12017501046A1 (enExample) |
| RU (1) | RU2017125365A (enExample) |
| SG (1) | SG11201704340VA (enExample) |
| TN (1) | TN2017000243A1 (enExample) |
| TW (1) | TW201628615A (enExample) |
| WO (1) | WO2016097933A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| CA3026512A1 (en) | 2016-06-13 | 2017-12-21 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
| MA55632A (fr) * | 2016-08-23 | 2022-02-16 | Ardelyx Inc | Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques |
| JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
| JP2019537557A (ja) | 2016-10-04 | 2019-12-26 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒアゴニストとしてのイソキサゾール類似体およびその使用方法 |
| AU2017339826A1 (en) * | 2016-10-05 | 2019-04-04 | Novartis Ag | Combination compositions comprising FXR agonists for treating or preventing a fibrotic,cirrhotic disease or disorder |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| EP4122464B1 (en) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
| NZ758117A (en) | 2017-04-12 | 2022-01-28 | Il Dong Pharma | Isoxazole derivatives as nuclear receptor agonists and uses thereof |
| MX2020000268A (es) * | 2017-07-06 | 2020-07-22 | Xuanzhu Biopharmaceutical Co Ltd | Agonista de fxr. |
| WO2019055808A1 (en) * | 2017-09-14 | 2019-03-21 | Ardelyx, Inc. | HORMONE RECEPTOR MODULATORS FOR THE TREATMENT OF MUTAGENIC AND FIBROTIC METABOLIC CONDITIONS AND DISORDERS |
| KR102731924B1 (ko) | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물 |
| JP7264905B2 (ja) | 2017-11-01 | 2023-04-25 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレーターとしての多環化合物 |
| KR102732404B1 (ko) | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 알켄 화합물 |
| SG11202003827YA (en) * | 2017-11-01 | 2020-05-28 | Bristol Myers Squibb Co | Bridged bicyclic compounds as farnesoid x receptor modulators |
| AU2018360575A1 (en) | 2017-11-01 | 2020-06-18 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| US11667629B2 (en) | 2017-12-22 | 2023-06-06 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Isoxazole derivative, preparation method therefor, and use thereof |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| KR20200138283A (ko) | 2018-03-22 | 2020-12-09 | 바이킹 테라퓨틱스 인코포레이티드 | 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법 |
| CN110357875B (zh) * | 2018-04-10 | 2022-06-21 | 浙江海正药业股份有限公司 | 氮杂双环辛烷类衍生物、其制备方法及其在医药上的用途 |
| CN110357876B (zh) * | 2018-04-10 | 2022-06-28 | 浙江海正药业股份有限公司 | 氮杂双环辛烷类衍生物及其制备方法和用途 |
| CN112334467B (zh) * | 2018-06-26 | 2023-06-20 | 轩竹生物科技股份有限公司 | Fxr受体激动剂 |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| LT3911647T (lt) | 2019-01-15 | 2024-03-25 | Gilead Sciences, Inc. | Izoksazolo junginys kaip fxr agonistas ir jį apimančios farmacinės kompozicijos |
| EP3919489A4 (en) * | 2019-01-31 | 2022-10-12 | The National Institutes of Pharmaceutical R&D Co., Ltd | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND MEDICAL USE |
| JP7465883B2 (ja) | 2019-02-15 | 2024-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとしての置換二環式化合物 |
| US12319676B2 (en) | 2019-02-15 | 2025-06-03 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid X receptor modulators |
| EP3924329A2 (en) | 2019-02-15 | 2021-12-22 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid x receptor modulators |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| CA3129949C (en) | 2019-02-19 | 2024-04-30 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| CN111825701B (zh) * | 2019-04-19 | 2023-12-08 | 正大天晴药业集团股份有限公司 | 含苯并噻唑的三环类fxr调节剂化合物 |
| US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| WO2021104022A1 (zh) * | 2019-11-29 | 2021-06-03 | 广东东阳光药业有限公司 | Tropifexor的新晶型及其制备方法 |
| WO2021104021A1 (zh) * | 2019-11-29 | 2021-06-03 | 广东东阳光药业有限公司 | Tropifexor的新晶型及其制备方法 |
| EP4090327B1 (en) | 2020-01-15 | 2025-03-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| EP4161925A4 (en) * | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
| EP4171600B1 (en) * | 2020-06-30 | 2024-11-27 | Sören OCVIRK | Pharmaceutical composition comprising a combination of a guanylate cyclase c (gucy2c) agonist and a short-chain fatty acid or prodrug thereof |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 |
| CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| CN113292555B (zh) * | 2021-04-28 | 2022-03-18 | 武汉纽瑞斯医药科技有限公司 | 一种Tropifexor的制备方法 |
| CN116987062A (zh) * | 2023-08-03 | 2023-11-03 | 中国热带农业科学院分析测试中心 | 一种氨基酸键联槟榔碱衍生物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009511450A (ja) * | 2005-10-07 | 2009-03-19 | ノバルティス アクチエンゲゼルシャフト | ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ |
| WO2012087520A1 (en) * | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2545964A1 (en) * | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
-
2015
- 2015-12-08 WO PCT/IB2015/059450 patent/WO2016097933A1/en not_active Ceased
- 2015-12-08 EP EP15813923.8A patent/EP3233083A1/en not_active Withdrawn
- 2015-12-08 AU AU2015365481A patent/AU2015365481B2/en not_active Ceased
- 2015-12-08 RU RU2017125365A patent/RU2017125365A/ru not_active Application Discontinuation
- 2015-12-08 TN TN2017000243A patent/TN2017000243A1/en unknown
- 2015-12-08 JP JP2017532168A patent/JP2017537960A/ja active Pending
- 2015-12-08 CA CA2970866A patent/CA2970866A1/en not_active Abandoned
- 2015-12-08 US US15/534,324 patent/US20170368038A1/en not_active Abandoned
- 2015-12-08 BR BR112017011972A patent/BR112017011972A2/pt not_active Application Discontinuation
- 2015-12-08 MX MX2017008057A patent/MX2017008057A/es unknown
- 2015-12-08 KR KR1020177019415A patent/KR20170095965A/ko not_active Withdrawn
- 2015-12-08 SG SG11201704340VA patent/SG11201704340VA/en unknown
- 2015-12-08 CN CN201580068503.5A patent/CN107106555A/zh active Pending
- 2015-12-17 TW TW104142545A patent/TW201628615A/zh unknown
-
2017
- 2017-06-01 IL IL252596A patent/IL252596A0/en unknown
- 2017-06-06 PH PH12017501046A patent/PH12017501046A1/en unknown
- 2017-06-16 CL CL2017001566A patent/CL2017001566A1/es unknown
-
2018
- 2018-09-20 US US16/137,360 patent/US20190083473A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017011972A2 (pt) | 2017-12-26 |
| EP3233083A1 (en) | 2017-10-25 |
| US20170368038A1 (en) | 2017-12-28 |
| MX2017008057A (es) | 2017-09-28 |
| AU2015365481B2 (en) | 2018-08-09 |
| CN107106555A (zh) | 2017-08-29 |
| TW201628615A (zh) | 2016-08-16 |
| US20190083473A1 (en) | 2019-03-21 |
| PH12017501046A1 (en) | 2017-11-27 |
| RU2017125365A (ru) | 2019-01-21 |
| KR20170095965A (ko) | 2017-08-23 |
| CA2970866A1 (en) | 2016-06-23 |
| JP2017537960A (ja) | 2017-12-21 |
| TN2017000243A1 (en) | 2018-10-19 |
| CL2017001566A1 (es) | 2018-03-23 |
| SG11201704340VA (en) | 2017-07-28 |
| WO2016097933A1 (en) | 2016-06-23 |
| RU2017125365A3 (enExample) | 2019-07-17 |
| AU2015365481A1 (en) | 2017-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252596A0 (en) | History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
| IL252943A0 (en) | Sunitinib formulations and methods of using them for the treatment of eye diseases | |
| ZA201608682B (en) | Boronic acid derivatives and therapeutic uses thereof | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| HUE055913T2 (hu) | Módszerek és készítmények a glioblastoma diagnosztizálására és kezelésére | |
| IL251477A0 (en) | Anti-ang2 antibodies and methods of use | |
| IL280690A (en) | Pharmaceutical preparations that include DGLA and their use | |
| IL247589A0 (en) | Dihydropyridine mgat2 inhibitors for use in the treatment of metabolic disorders | |
| IL250484B (en) | Heterovesicular compounds and their use in the treatment of tuberculosis | |
| EP3117827A4 (en) | Composition for vagina and use of the composition | |
| EP3137907A4 (en) | Methods and compositions for the diagnosis and treatment of kawasaki disease | |
| SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
| IL246855A0 (en) | Materials for use in the treatment of retinitis | |
| IL246587A0 (en) | Preparations for use in the treatment of allergic conditions | |
| IL251407B (en) | A multivalent compound for the treatment and prevention of brain damage | |
| HK1236834A1 (en) | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
| PL3370727T3 (pl) | Nieulegające biokonwersji c3-podstawione pochodne pregnenolonu do zastosowania w leczeniu zaburzeń związanych z nadużywaniem substancji | |
| HK1233709A1 (en) | Methods and compositions for the diagnosis and treatment of kawasaki disease | |
| ZA201408464B (en) | Composition for the use in treatment of asthma |